A new tool to search for medicines that might treat neurodegenerative diseases linked to problems with mitochondria, including amyotrophic lateral sclerosis (ALS), has been developed by a team of scientists at the Scripps Research Institute, a study reports.  This tool…

At the time of his stunning 2015 amyotrophic lateral sclerosis (ALS) diagnosis, Ed Rapp was a veteran Caterpillar executive who had worked and lived around the world. Since being diagnosed, Rapp has directed his efforts toward ALS advocacy. Those efforts will be recognized on Feb. 22, when he…

A single protein called Gemin3 may be the bridge linking the varied proteins known to underlie amyotrophic lateral sclerosis (ALS), suggesting a common pathway in this disease, a study using a fruit fly model showed.  The discovery of this common…

Bloom Science and Duke University have entered into an exclusive licensing agreement that provides the biopharmaceutical company access to the intellectual property and technology related to unique strain isolates and genetic variants of Akkermansia genus bacteria. This type of bacteria has been demonstrated to slow disease progression…

The presence of autoantibodies against a calcium channel in people with amyotrophic lateral sclerosis (ALS) may explain the frequent development of type 2 diabetes in these patients, a preclinical study suggests. The data, which pinpoint the toxic effects of these autoantibodies in mouse insulin-secreting pancreatic cells, shed light on…

AI Therapeutics‘ lymphoma candidate LAM-002 was identified by the company’s artificial intelligence-based platform — called Guardian Angel — as a possible treatment for amyotrophic lateral sclerosis (ALS). Researchers from AI have already tested and confirmed LAM-002’s therapeutic potential in an ALS context. Now, an independent…

A $1 million gift from the Manouk Djoukhadjian Family Foundation II will create Quebec’s first philanthropic research chair on amyotrophic lateral sclerosis (ALS). The donation to the Armand-Frappier Foundation will establish the Anna Sforza Djoukhadjian Philanthropic Research Chair to advance ALS research at the Institut national…

Stealth BioTherapeutics announced the initiation of a Phase 1 trial to assess the safety and tolerability of its investigational oral treatment, SBT-272, in healthy volunteers. SBT-272 is being developed to treat neurodegenerative diseases marked by problems in the workings of mitochondria (a cell’s powerhouse), including amyotrophic lateral sclerosis…

The U.S. Food and Drug Administration (FDA) has authorized the evaluation of the first three candidate therapies for amyotrophic lateral sclerosis (ALS) in the HEALEY ALS Platform Trial. This trial model, designed to accelerate the development of ALS therapies by assessing multiple treatment candidates simultaneously, is the first of…

Athletes who played professional football — known as soccer in the U.S. — are more than three times more likely to die of a neurodegenerative disease than are the general population, a study from Scotland has found. Its researchers compared causes of death over 18 years for about 7,700 former professional…